CSRxP: New Study Underscores Big Pharma The Only Rebate Rule Winner

Avalere Health Finds Proposed Rule Could Hike Premiums 40 Percent, Cost Taxpayers Over $400 Billion


For Immediate Release

Contact: Jon Conradi


[email protected]


Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Monday reacting to a new study, conducted by Avalere Health, analyzing three scenarios projecting the impact of the Rebate Rule proposed by the U.S. Department of Health and Human Services (HHS).

“These new findings add staggering context to what we already know: the only guaranteed winner from the proposed Rebate Rule is Big Pharma,” said CSRxP executive director Lauren Aronson.  “If this misguided regulation advances, Big Pharma stands to reap billions in new profits, while seniors and the disabled face painful premium hikes and taxpayers are forced to cover hundreds of billions in increased drug spending.”

The Avalere Health report, commissioned by America’s Health Insurance Plans (AHIP), projected the impact on stakeholders if drug makers withheld 30 or 50 percent of rebates.  The study undercut the entire premise of the Rebate Rule by projecting that out-of-pocket costs for beneficiaries under the 50 percent scenario would increase by more than $36 billion.

Avalere’s key findings if drug makers held back 50 percent of rebates include:

These findings added greater context on potential outcomes to the initial report from the Center for Medicare and Medicaid Services’ (CMS) Office of the Actuary (OACT) that projected manufacturers would hold back 15 percent of rebates under the rule, resulting in:

“The proposed rule places trust in Big Pharma, which has a demonstrated track record of anti-competitive behavior and price gouging, returning the full amount of rebates out of the goodness of their hearts,” Aronson continued.  “There is little question Big Pharma will be eager to hold back rebates, lining their own pockets at massive cost to seniors and taxpayers.”

“The administration is working on several commendable efforts to reduce prescription drug prices,” Aronson added.  “But the proposed Rebate Rule would be a massive step backwards that trades guaranteed negative impacts on seniors and taxpayers for theoretical and questionable price benefits.  We urge the administration to ditch the rule and focus on market-based solutions to introduce more competition into the prescription drug market to lower prices.”

AHIP is a member of CSRxP, a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, and businesses – promoting bipartisan, market-based solutions to lower drug prices in America.


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.